Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004850-97
    Sponsor's Protocol Code Number:13-21
    National Competent Authority:Ireland - HPRA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-11-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedIreland - HPRA
    A.2EudraCT number2013-004850-97
    A.3Full title of the trial
    A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Radium-223 & Enzalutamide metastatic prostate cancer study
    A.3.2Name or abbreviated title of the trial where available
    Radium-223 & Enzalutamide in mCRPC
    A.4.1Sponsor's protocol code number13-21
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCancer Trials Ireland
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer Healthcare Ireland
    B.4.2CountryIreland
    B.4.1Name of organisation providing supportAstellas Ireland
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCancer Trials Ireland
    B.5.2Functional name of contact pointHead of Clinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, Old Finglas Road, Glasnevin
    B.5.3.2Town/ cityDublin
    B.5.3.3Post codeD11 KXN4
    B.5.3.4CountryIreland
    B.5.4Telephone number+35316677211
    B.5.5Fax number+35316697869
    B.5.6E-mailregulatory@cancertrials.ie
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Xofigo
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRadium-223
    D.3.9.1CAS number 15623-45-7
    D.3.9.3Other descriptive nameRADIUM-223
    D.3.9.4EV Substance CodeSUB73830
    D.3.10 Strength
    D.3.10.1Concentration unit KBq/Kg kilobecquerel(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product Yes
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Xtandi
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNENZALUTAMIDE
    D.3.9.1CAS number 915087-33-1
    D.3.9.4EV Substance CodeSUB77412
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic castrate-resistant prostate cancer
    E.1.1.1Medical condition in easily understood language
    Metastatic castrate-resistant prostate cancer
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060862
    E.1.2Term Prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary Objective:
    To determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer. Toxicities will be recorded and graded according to the NCI - CTCAE criteria, version 4.
    E.2.2Secondary objectives of the trial
    Secondary Objectives:

    1. To examine the objective time to clinical/radiological progression of patients treated with Radium-223 in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.

    2. To examine the objective time to PSA progression of patients treated with Radium-223 in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.

    3. To assess PSA response (50% reduction from baseline).

    4. To assess Change in alkaline phosphatase

    5. To measure the time to first skeletal-related event.

    6. To assess pain (Brief Pain Inventory-Short Form)

    7. To measure overall survival.

    8. Translational sub-study: To examine potential biomarkers of enzalutamide resistance in circulating tumour cells, whole blood, plasma & Serum.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    To examine potential biomarkers of enzalutamide resistance in circulating tumour cells.
    Version 2, dated 25-Apr-2014.
    E.3Principal inclusion criteria
    Inclusion Criteria:
    1. Written informed consent obtained prior to any study-related procedures
    2. Age ≥ 18 years and male.
    3. ECOG performance status ≤ 2.
    4. Histologically/cytologically confirmed adenocarcinoma of the prostate, and without neuroendocrine differentiation or small cell histology.
    5. Metastatic disease as confirmed by CT/MRI or bone scan
    6. Patients must have documented Progressive disease (PD) either by radiological or PSA criteria as defined in a) and b) below:

    a) For the radiological PD assessment, 2 sets of scans using the same imaging modality (ie CT/MRI or bone scan) and taken at separate time points are required to document radiological disease progression during or following the patient’s most recent anti-neoplastic therapy, (note: the 1st bone scan can be from before most recent therapy but the 2nd scan must show disease progression during or after the most recent therapy).
    For patients with bone disease, progression will be assessed following recommendations by the Prostate Cancer Working Group (PCWG2): appearance of 2 or more new lesions on bone scan, confirmed, if necessary, by other imaging modalities (such as CT scan or MRI), if results of the bone scans are ambiguous).
    For patients with soft tissue lesions progression will be assessed using RECIST 1.1 criteria. Patients may have measurable or non-measurable disease according to RECIST criteria version 1.1.

    b) PSA progression is defined as an increase in PSA, as determined by 2 separate measurements taken at least 1 week apart and confirmed by a third. If the third measurement is not greater than the second measurement, then a fourth measurement must be taken and must be greater than the second measurement for the patient to be eligible for the study. Furthermore, the confirmatory PSA measurement (i.e. the third or, if applicable, fourth PSA measurement) must be defined. If a patient has received prior anti-androgen therapy (e.g. bicalutamide), PSA progression must be evident and documented after discontinuation of anti-androgen therapy, (note: The 1st PSA reading taken to document disease progression when the patient presents can be while the patient is on Casodex or other ADT).

    7. Prior surgical castration or concurrent use of an agent for medical castration (e.g. GnRH analogue) with testosterone at screening less than 50ng/dL.
    8. Screening PSA ≥ 2ng/mL.
    9. Patients, even if surgically sterilized (i.e. status post-vasectomy), who:
    - will abstain from intercourse
    - or must agree to use barrier contraception during and for 6 months after discontinuation of study treatment.
    - If the patient engages in sexual intercourse with a woman of childbearing potential, a condom and another form of birth control must be used during and for 6 months after treatment.
    10. Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 28 days prior to registration.
    11. Life expectancy of 12 months or more based on general health and prostate cancer disease status as judged by the investigator.
    12. Documented presence of osseous metastases with or without visceral involvement / lymph nodes.
    13. Able to swallow study drug as whole tablet.
    14. Adequate haematological, hepatic, and renal function.
    • Haemoglobin ≥ 10g/dL.
    • Neutrophils (ANC/AGC) ≥1500/mm³ (1.5 x 10^9/L).
    • Platelets ≥ (100 x 10^9/L).
    • Total bilirubin ≤ 1.5mg/dL (25.65 μmol/L) with the exception of Gilberts syndrome.
    • Both ALT (SGPT) and AST (SGOT) ≤ 3 x ULN with or without liver Metastasis.
    • Serum creatinine ≤1.5 ULN or calculated creatinine clearance (CrCl) ≥ 50mL/min according to the Cockcroft and Gault formula.
    15. Continuous daily use of oral prednisone, oral dexamethasone, or other systemic corticosteroids is allowed prior to study entry but must be discontinued a minimum of 2 weeks prior to start of study treatment.
    E.4Principal exclusion criteria
    Exclusion criteria:
    1. Patients receiving any other investigational agents (within 30 days prior to registration).

    2. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis).
    3. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment).
    4. Prior therapy with orteronel, ketoconazole, aminoglutethimide, abiraterone or enzalutamide.
    5. All anti-androgen therapy (including bicalutamide) is excluded within 6 weeks prior to first dose of study drug. Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (eg, finasteride or dutasteride), must be discontinued 2 weeks before the first dose of study drug. [bisphosphonates and Denosumab are allowed concomitant medications].
    6. Prior chemotherapy for prostate cancer, with the exception of:
    - neoadjuvant/ adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening.
    -Patients who received prior docetaxol for castrate sensitive metastatic prostate cancer commencing within 120 days of ADT initiation where total dose received did not exceed 450mg/m2
    7. Prior exposure to radioisotope therapy; Prior exposure to bone directed radioisotope therapy, eg samarium 153, strontium 90.
    8. Exposure to external beam radiation within 4 weeks prior to receiving the first dose of study drug. Patients must also have recovered from all treatment-related toxicities.

    In patients with untreated imminent or established spinal cord compression, treatment with standard of care, as clinically indicated, should be completed before starting treatment with Ra-223 dichloride (Xofigo®).

    9. Diagnosis of or treatment for another systemic malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma
 in situ of any type are not excluded if they have undergone complete resection.
    10.History of myocardial infarction, unstable symptomatic ischemic heart disease/ unstable angina, uncontrolled on-going arrhythmias of Grade >2 (National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4), pulmonary embolism, or any other cardiac condition (e.g. pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug. Patients with long QT, QTcF >470ms or uncontrolled hypertension are excluded.
    11.New York Heart Association Class III or IV heart failure (see Appendix L).
    12.History of seizure, underlying brain injury with loss of consciousness, stroke, Transient Ischaemic attack (TIA), cerebral vascular accident , primary brain tumours or brain metastases, brain arteriovenous malformation, alcoholism, or the use of concomitant medications that may lower the seizure threshold.
    13. Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any ongoing serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with participation in this study. Patients will be tested for hepatitis B or C or HIV infection during screening if they are considered by the investigator to be at higher risk for these infections and have not been previously tested, or if testing is required by the independent ethics committee or institutional review board.
    14. Prohibited medications, including drugs that may affect exposure to enzalutamide i.e. study drugs that induce or inhibit CYP3A4, CYP2C8, and CYP2C9 (See section 6.4.3 and also Appendix H).
    E.5 End points
    E.5.1Primary end point(s)
    Primary Endpoint:
    • The incidence of grade 3 or higher adverse events during the period of combination therapy will be recorded and graded according to the NCI - CTCAE criteria, version 4.

    The grade 3/4 toxicity rate will be presented as the percentage of patients in the safety population who experienced a grade 3 or higher toxicity, together with the accompanying two-sided 90% confidence interval using normal approximation.
    The primary analysis will be performed for the safety population, defined as all registered patients who received at least one dose of study treatment.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary analysis will be performed for the safety population, defined as all registered patients who received at least one dose of study treatment.
    E.5.2Secondary end point(s)
    Secondary Endpoints:
    • Time to clinical/radiological progression (as measured according to the PCWG2 and RECIST 1.1 criteria);
    • Time to PSA progression (as measured according to the PCWG2 criteria);
    • PSA response (50% reduction from baseline);
    • Change in alkaline phosphatase;
    • Time to first skeletal-related event;
    • Pain assessment (Brief Pain Inventory-Short Form);
    • Overall survival;
    • Translational sub-study: To examine potential biomarkers of enzalutamide resistance in circulating tumour cells, whole blood, plasma and serum.

    Efficacy endpoints will be analysed for the intention-to-treat population, defined as all registered patients regardless of whether they received study treatment or not.
    Clinical and PSA progression-free survival probabilities over time will be estimated using the Kaplan-Meier method, presenting estimates of median PFS with 95% confidence intervals (CIs), also estimates of PFS and 95% CIs at 12 months.
    Overall survival and time to first skeletal-related event will be analysed similarly to radiological and PSA progression-free survival.
    Descriptive statistics will be presented for pain as assessed by the Brief Pain Inventory-Short Form.
    Regarding the translational sub-study, the statistical analysis of the data will employ an evaluation of the clinical sensitivity and specificity of the studied biomarkers to predict favourable response to therapy. Confidence intervals will be prepared for each statistic. As exact biomarker levels are not known, the study has assumed that biomarker (mutation) positivity may be up to 0.5% in Enzalutamide sensitive patients but should increase to approximately 1.0% or greater when detected in CTCs or cfDNA.
    E.5.2.1Timepoint(s) of evaluation of this end point
    A median of 16.5 months for radiological progression free survival would indicate efficacy of treatment, and less than 8 months would indicate futility. A median of 11 months for PSA progression free survival would indicate efficacy, and less than 5.6 months would indicate futility. The planned sample size of 44 patients would be sufficient to provide 90% power (at a 5% significance level) to distinguish between an unacceptable median of 8 months for radiological PFS and an acceptable median of 16.5 months, assuming an accrual period of 12 months and a statistical analysis time point of 12 months after the last patient enters the study. This sample size would also provide 90% power to distinguish between an unacceptable median of 5.6 mnths for PSA PFS and an acceptable median of 11 mnths.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as when all enrolled patients have completed either a treatment and/or study withdrawal visit.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 33
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 11
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state44
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    All patient adverse events will be followed up for the study for safety reasons for 30 days after the last study treatment. For any patients who are withdrawn from the study for reasons other than for progressive disease, the patients will be followed off-study in accordance with standard of care for tumour response every 12(+/-1) weeks until disease progression.
    All patients will be followed for survival every 3 months for 2 years after the study withdrawal visit, or until study close out.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-07-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-07-01
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-11-23
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 20:31:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA